Health Care Supplies

Bausch + Lomb

Bausch + Lomb to Host R&D Contact Lens Project Webinar

Bausch + Lomb released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 1.244 B (forecast USD 1.216 B), actual EPS USD -0.2 (forecast USD -0.1475)

Bausch + Lomb to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 1.215 B, EPS USD -0.1475

Bausch + Lomb released FY2025 annual earnings on February 18 Pre-Market EST, actual revenue USD 0 (forecast USD 5.079 B), actual EPS USD 0 (forecast USD -0.744)

Bausch + Lomb released FY2025 Q4 earnings on February 18 Pre-Market (EST), actual revenue USD 1.405 B (forecast USD 1.385 B), actual EPS USD -0.1701 (forecast USD 0.1375)

Bausch + Lomb to Release FY2025 Q4 Earnings on February 18, 2026 Pre-Market EST, Forecast Revenue USD 1.385 B, EPS USD 0.1375

Bausch + Lomb Executives to Speak at JPM Healthcare Conference

Needham Maintains Hold Rating on Bausch + Lomb and Adjusts Financial Model

Wells Fargo analyst reiterates Bausch + Lomb hold rating, target price at $17.00

US Bank Maintains Sell Rating on Bausch + Lomb

Bausch + Lomb Outlines Three-Year Growth Strategy

Bausch + Lomb Highlights Strong Revenue Growth and Maintains Full-Year Guidance

Bausch + Lomb released FY2025 9 Months earnings on October 29 After-Market (EST), actual revenue USD 3.696 B, actual EPS USD -0.8609

Bausch + Lomb released FY2025 Q3 earnings on October 29 After-Market EST, actual revenue USD 1.281 B (forecast USD 1.278 B), actual EPS USD -0.08 (forecast USD -0.072)

Thomas Stephan Rates Bausch + Lomb Corporation as Hold

Bausch + Lomb to release FY2025 Q3 earnings on October 29 After-Market EST, forecast revenue USD 1.277 B, EPS USD -0.07

Jana Partners Builds Stake in Cooper Companies and Pushes for Potential Contact Lens Unit Merger

Bausch & Lomb Corp Publishes Q2 2025 Earnings Report

Bausch + Lomb released FY2025 Semi-Annual earnings on July 30 During-Market EST, actual revenue USD 2.415 B, actual EPS USD -0.78

Bausch + Lomb released FY2025 Q2 earnings on July 30 During-Market EST, actual revenue USD 1.278 B (forecast USD 1.256 B), actual EPS USD -0.18 (forecast USD -0.188)

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

MetaVia

Silexion Therapeutics

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Pinned News

置顶新闻

Better Futures raises EUR 600,000 from Enterprise Ireland, angel investors

ABBNY

BLCO

Better Futures, an Irish AI company, has raised EUR 600,000 in a funding round led by angel investors and Enterprise Ireland. This brings total funding to EUR 1.1 million, which will be used for product development and hiring in Dublin to enhance its EVA platform for regulated industries. Early customers include ABB and Bausch + Lomb.

PUBT

ABB Ltd

09:55 AM EST - Bausch + Lomb Corporation : Announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex. Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the most advanced PreserVision formula, intended to support a broader range of people, including those in earlier stages. Bausch + Lomb Corporation shares T.BLCO are trading up $0.16 at $22.54.

Baystreet

Stocks in Play: Bausch + Lomb Corporation

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

StockTitan

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

H.C. Wainwright analyst Yi Chen has reiterated a Buy rating on Bausch + Lomb Corporation (BLCO) with a price target of $20.00. Chen, who focuses on the Healthcare sector, has an average return of 0.2% and a 40.89% success rate on his stock recommendations. Additionally, Citi's Joanne Wuensch also issued a Buy rating for Bausch + Lomb, while Stifel Nicolaus maintained a Hold rating on the same day.

Tip Ranks

Ocular Therap

Opko Health

Caredex

Citigroup

Stifel Financial

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

Stifel Nicolaus analyst Thomas Stephan has maintained a Hold rating on Bausch + Lomb Corporation (BLCO) with a price target of $16.00. He has an average return of 2.1% and a 40% success rate on his stock recommendations. Additionally, Barclays also issued a Hold rating, while Citi maintained a Buy rating on the company.

TransMedics

Glaukos

Alphatec

Barclays

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Needham analyst David Saxon has maintained a Hold rating on Bausch + Lomb (BLCO) stock due to strong Q1 performance, including revenue and EBITDA exceeding expectations, and positive momentum in the pharmaceuticals division. However, uncertainty surrounding the company's planned spin-off from Bausch Health Companies tempers this outlook. Barclays also reiterated a Hold rating with a $20.00 price target.

Bausch Health

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

Earnings Watch

Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B

Bausch + Lomb reported first-quarter 2026 revenue of $1.244 billion, a 9% increase from the previous year. The company raised its full-year guidance based on strong performance, including double-digit growth in its Pharmaceuticals segment, driven by MIEBO and XIIDRA. Despite a GAAP net loss of $71 million, adjusted EBITDA reached $189 million. Key highlights include successful product launches and advancements in R&D, with a focus on operational efficiencies through AI adoption.

MorningStar

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Bausch + Lomb(BLCO.US)

Better Futures raises EUR 600,000 from Enterprise Ireland, angel investors

Stocks in Play: Bausch + Lomb Corporation

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Trending